Key Stats for Cardinal Health Stock
- Past-Week Performance: +2%
- 52-Week Range: $120.7 to $233.6
- Current Price: $229.9
What Happened?
Cardinal Health (CAH) just raised its full-year EPS guidance to $10.15–$10.35, a 23% to 26% growth projection that firmly dismantles any remaining case for treating this as a slow-growth logistics name.
On February 5, CFO Aaron Alt and CEO Jason Hollar unveiled non-GAAP diluted EPS of $2.63, a 36% year-over-year jump, prompting multiple Wall Street desks to immediately revise their price targets upward.
The engine behind that beat was Pharmaceutical and Specialty Solutions, where segment profit surged 29% to $687 million, driven by specialty distribution, MSO platforms, and a generics program posting unit growth above long-term expectations.
Consequently, the market is rapidly re-rating Cardinal Health from a low-margin drug distributor to a specialty-driven growth platform, with specialty revenues now on track to surpass $50 billion in fiscal 2026 and a 3-year specialty CAGR lifted to 16%.
CFO Aaron Alt stated on the Q2 earnings call that “our new range is $10.15 to $10.35, up from the at least $10 interim guidance update,” representing 23% to 26% year-over-year EPS growth that exceeded prior consensus expectations.
Supporting that optimism, Wells Fargo raised its price target to $256 from $237 on February 10, while JP Morgan lifted its target to $243 from $209 on the same date, reflecting broad institutional conviction in the raised guidance trajectory.
Looking further out, Cardinal Health’s push toward $1 billion in Biopharma Services revenue by fiscal 2028, combined with its three MSO platforms across oncology, autoimmune, and urology, positions it to capture an outsized share of the specialty pharmaceutical distribution market over the next three to five years.
Wall Street’s Take on CAH Stock
Cardinal Health’s Q2 beat, paired with its second consecutive guidance raise to $10.15–$10.35 EPS, directly signals that fiscal 2026 earnings momentum is accelerating faster than the Street had modeled.
The fundamental case is compelling: forward revenue is projected to grow 16.2% to $258.7 billion in fiscal 2026, while normalized EPS is forecast to reach $10.31, representing 25.1% year-over-year growth.
Meanwhile, 11 analysts rate CAH a Buy, 2 rate it Outperform, and 4 rate it Hold, with a mean price target of $248.80, implying 8.2% upside from the March 2 close of $229.88.
The analyst target range spans $200.00 on the low end to $270.00 on the high end, with the high case hinging on continued specialty profit outperformance and successful Solaris Health integration driving incremental distribution revenue.
What Does the Valuation Model Say?
The TIKR valuation model sets a mid-case target of $279.89, implying 21.8% total return over 4.3 years at a 4.6% annualized IRR from the current price of $229.88.
The market still prices CAH like a thin-margin drug distributor, yet its specialty segment alone is on track to surpass $50 billion in revenue this fiscal year.
Additionally, EBITDA is forecast to expand 27.3% in fiscal 2026, a growth rate that sharply contradicts the low-margin narrative still embedded in the stock’s valuation.
Management’s commitment to $1 billion in Biopharma Services revenue by fiscal 2028, anchored by Sonexus growing 30%-plus, signals this is a platform re-rating, not a one-quarter anomaly.
The primary risk is tariff-driven margin compression in GMPD, where adverse net tariff impact already partially offset Q2’s $37 million segment profit, threatening the turnaround trajectory.
Investors should watch the Q3 GMPD segment profit result closely, as management flagged that Cardinal Health brand distributor buying patterns will normalize, creating a sequential profit headwind.
CAH is undervalued at $229.88 given 25.1% forward EPS growth, but the re-rating fully materializes only when the GMPD turnaround posts consecutive clean quarters.
Should You Invest in Cardinal Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CAH stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Cardinal Health, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CAH stock on TIKR for Free →
